VARIPED

Description

VARIPED is a lyophilized preparation of the Oka strain of live, attenuated varicella virus.   VARIPED is indicated for active immunization for the prevention of Varicella (Chickenpox) in individuals 12 months of age and older. Varicella vaccine is a lyophilized preparation containing sucrose, phosphate, glutamate, processed gelatin, and urea as stabilizers.

Immunization Guideline:

Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.

• In children (12 months to 12 years of age), 2 doses at a minimum interval of 3 months should be given

• In adolescents (≥13 years of age), 2 dose at a minimum interval of 4 weeks should be given

• In adults 2 doses, to be administered at minimum interval of 4 weeks should be given

For latest IAP updates see revised immunization schedule. VARIPED can be administered concomitantly with M M R* II (Measles, Mumps, and Rubella Virus Vaccine Live), TETRAMUNE** (diphtheria and tetanus toxoids and pertussis vaccine adsorbed and Haemophilus b conjugate vaccine), or COMVAX* (Haemophilus influenzae type b conjugate and hepatitis B vaccine). If VARIPED is not given together with M M R II, a 1 month interval between the 2 live virus vaccines should be observed.

Additional information

manufacturer

Merck Sharp & Dohme Corp

country-of-manufacture

USA

vaccine-type

chickenpox

pharmaceutical-form

Lyophilized

package-size

1 Dose

route-of-administration

Subcutaneous

preservative

None

Contraindications

History of severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of varicella vaccine. Primary or acquired immunodeficiency states. Any febrile illness or active infection, including untreated tuberculosis. Pregnancy.